Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2024-10-25 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
2024年三季度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled '云南沃森生物技术股份有限公司2024 年第三季度报告' which translates to 'Yunnan Watson Biotechnology Co., Ltd. 2024 Third Quarter Report'. It contains detailed financial data including income statement, balance sheet, cash flow statement, and explanations of financial changes for the third quarter of 2024. The document includes comprehensive financial metrics, non-recurring gains and losses, shareholder information, and other important matters related to the quarter. The length is about 15,000 characters, indicating a full report rather than a brief announcement. The content is consistent with an Interim / Quarterly Report as it covers a period shorter than a full fiscal year with substantive financial data and analysis. Therefore, the document should be classified as an Interim / Quarterly Report (IR). Q3 2024
2024-10-25 Chinese
第五届监事会第十八次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Yunnan Watson Biotechnology Co., Ltd. regarding the review and approval of the company's 2024 third quarter report and related impairment provisions. It states that the Supervisory Board has audited and approved the 2024 Q3 report and related accounting decisions, but the actual 2024 Q3 report is hosted on an external site (the designated information disclosure website). The document itself is short (1218 characters) and does not contain the full financial statements or substantive financial data, but rather the Supervisory Board's meeting resolution and approval of the report. This fits the pattern of a Regulatory Filing (RNS) as it is an official announcement related to regulatory compliance and internal approvals, not the full interim report itself. Therefore, the correct classification is Regulatory Filings (RNS).
2024-10-25 Chinese
2024年第三季度报告披露提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (397 characters) indicating that the company has disclosed its 2024 third quarter report on a regulatory website. It states the report was approved by the board and is available for investors to review. There is no actual financial data or detailed report content included, only a notice of the report's publication. According to the 'MENU VS MEAL' rule, this is a Report Publication Announcement (RPA), not the report itself (IR).
2024-10-25 Chinese
重大信息内部报告制度（2024年10月）
Governance Information Classification · 95% confidence The document is titled '云南沃森生物技术股份有限公司 重大信息内部报告制度' which translates to 'Yunnan Watson Biotechnology Co., Ltd. Major Information Internal Reporting System'. The content describes the internal procedures and responsibilities for reporting major events or information that could impact the company's stock price or investment decisions. It outlines definitions, scope of major events, reporting procedures, confidentiality obligations, management responsibilities, and legal compliance related to internal reporting of significant company information. There are no financial statements, earnings data, audit results, or investor presentations. The document is a governance-related internal policy document focused on information disclosure and compliance with securities laws and stock exchange rules. It does not announce or contain financial results, voting outcomes, or capital changes. It is not a report publication announcement or a regulatory filing in the usual sense but a detailed governance and compliance policy document. Therefore, the most appropriate classification is Governance Information (CGR).
2024-10-25 Chinese
投资者关系管理制度（2024年10月）
Governance Information Classification · 95% confidence The document is titled '云南沃森生物技术股份有限公司 投资者关系管理制度' which translates to 'Yunnan Watson Biotechnology Co., Ltd. Investor Relations Management System.' It outlines the principles, responsibilities, and procedures for managing investor relations, including communication methods, confidentiality, roles of the board secretary, and record-keeping of investor activities. There are no financial statements, earnings data, or regulatory filings of financial results. The document is a policy or governance document related to investor relations management rather than a report or announcement of financial results or corporate actions. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The content aligns best with Governance Information (CGR), as it details internal rules and governance practices related to investor relations management.
2024-10-25 Chinese
第五届董事会第二十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 24th meeting of the 5th Board of Directors of Yunnan Watson Biotechnology Co., Ltd. It includes details about the meeting date, attendance, and voting results on various agenda items such as approval of the 2024 Q3 report, impairment provisions, and revisions to internal management systems. The document does not contain the full quarterly report or detailed financial statements but references that the 2024 Q3 report is available on the designated disclosure website. The document is relatively short (2292 characters) and serves as a meeting resolution announcement rather than the report itself. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2024-10-25 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.